标题/作者	年份
ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells DW Lee, BD Santomasso, FL Locke, A Ghobadi, CJ Turtle, JN Brudno, ... Biology of blood and marrow transplantation 25 (4), 625-638	2019
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study JS Abramson, ML Palomba, LI Gordon, MA Lunning, M Wang, J Arnason, ... The Lancet 396 (10254), 839-852	2020
Mechanisms of resistance to CAR T cell therapy NN Shah, TJ Fry Nature reviews Clinical oncology 16 (6), 372-385	2019
Targeting the NLRP3 inflammasome in severe COVID-19 TL Freeman, TH Swartz Frontiers in immunology, 1518	2020
Cytokine release syndrome with chimeric antigen receptor T cell therapy N Frey, D Porter Biology of Blood and Marrow Transplantation 25 (4), e123-e127	2019
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma MC Pasquini, ZH Hu, K Curran, T Laetsch, F Locke, R Rouce, ... Blood advances 4 (21), 5414-5424	2020
The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden B Santomasso, C Bachier, J Westin, K Rezvani, EJ Shpall American Society of Clinical Oncology Educational Book 39, 433-444	2019
Managing the toxicities of car T‐cell therapy SS Neelapu Hematological oncology 37, 48-52	2019
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations R Weinkove, P George, N Dasyam, AD McLellan Clinical & translational immunology 8 (5), e1049	2019
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity S Yu, M Yi, S Qin, K Wu Molecular cancer 18 (1), 1-13	2019
Neurotoxicity associated with CD19-targeted CAR-T cell therapies J Gust, A Taraseviciute, CJ Turtle CNS drugs 32, 1091-1101	2018
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy ML Schubert, M Schmitt, L Wang, CA Ramos, K Jordan, C Müller-Tidow, ... Annals of oncology 32 (1), 34-48	2021
CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products JC Chavez, C Bachmeier, MA Kharfan-Dabaja Therapeutic advances in hematology 10, 2040620719841581	2019
Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia NV Frey, PA Shaw, EO Hexner, E Pequignot, S Gill, SM Luger, ... Journal of Clinical Oncology 38 (5), 415	2020
Cytokine release syndrome and neurotoxicity after CD 19 chimeric antigen receptor‐modified (CAR‐) T cell therapy KA Hay British journal of haematology 183 (3), 364-374	2018
CAR T cell therapies for patients with multiple myeloma L Mikkilineni, JN Kochenderfer Nature reviews Clinical oncology 18 (2), 71-84	2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events MV Maus, S Alexander, MR Bishop, JN Brudno, C Callahan, ML Davila, ... Journal for immunotherapy of cancer 8 (2)	2020
Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy LL Riegler, GP Jones, DW Lee Therapeutics and clinical risk management, 323-335	2019
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains KM Cappell, JN Kochenderfer Nature reviews Clinical oncology 18 (11), 715-727	2021
Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features X Zhang, X Lu, J Yang, G Zhang, J Li, L Song, Y Su, Y Shi, M Zhang, J He, ... Blood Advances 4 (10), 2325-2338	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。